董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel Hume | 男 | Director | 56 | 39.50万美元 | 未持股 | 2023-05-01 |
| Sagar Lonial | 男 | Director | 56 | 39.25万美元 | 未持股 | 2023-05-01 |
| Laurence N. Charney | 男 | Lead Independent Director | 76 | 43.75万美元 | 未持股 | 2023-05-01 |
| Michael S. Weiss | 男 | Chairman, Chief Executive Officer and President | 57 | 1043.52万美元 | 未持股 | 2023-05-01 |
| Yann Echelard | 男 | Director | 59 | 39.50万美元 | 未持股 | 2023-05-01 |
| Kenneth Hoberman | 男 | Director | 58 | 39.75万美元 | 未持股 | 2023-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael S. Weiss | 男 | Chairman, Chief Executive Officer and President | 57 | 1043.52万美元 | 未持股 | 2023-05-01 |
| Sean A. Power | 男 | Chief Financial Officer, Treasurer and Corporate Secretary | 41 | 196.59万美元 | 未持股 | 2023-05-01 |
董事简历
中英对照 | 中文 | 英文- Daniel Hume
-
Daniel Hume自2015年6月起担任公司董事。Hume现任Kirby McInerney, LLP纽约办事处合伙人，是公司管理委员会成员。Hume的法律业务范围包括证券、结构金融、反信托诉讼和合规。Hume于1995年加入Kirby McInerney, LLP.自此之后，在他的职业生涯中Hume一直为企业、公共和个人客户提供建议，包括世界上一些大型的机构投资者并帮助他们恢复损失的上百万美元。他的工作为他带来了荣誉和赞许，包括最近被提名为National Law Journal “hot”list 以及2013年度law360 “most feared”list。Hume获许在纽约州和联邦法庭实践法律，包括the United States District Courts for the Southern and Eastern Districts of New York；the United States Court of Appeals for the Second, Fourth, and Fifth Circuits；the Appellate Division of the Supreme Court of the State of New York, First Judicial Department， 以及the United States Supreme Court。他于1988年毕业于奥尔巴尼the State University of New York，持有哲学文学学士学位；Columbia Law School的Columbia Journal of Environmental Law注明编辑，1991年获得法律博士学位。
Daniel Hume has served on board of directors since October 28, 2025. Mr. Hume currently serves as the Managing Partner of Kirby McInerney, LLP, where his practice foces on securities law regulation, structured finance, antitrt, and civil litigation, and where he has practiced law since 1995. Since June 2015, Mr. Hume has served as a director of TG Therapeutics, Inc., a public biopharmaceutical company and Lirum Therapeutics, a private biopharmaceutical company. Previoly, Mr. Hume was a director of Stemline Therapeutics Inc., a late clinical stage biopharmaceutical company, from 2017 to 2021, and National Holdings Corporation, a financial services company, from 2016 to 2021, until those companies' successful acquisitions. Mr. Hume earned a B.A. in philosophy from the State University of New York at Albany and earned a J.D. from the Columbia University Law School. - Daniel Hume自2015年6月起担任公司董事。Hume现任Kirby McInerney, LLP纽约办事处合伙人，是公司管理委员会成员。Hume的法律业务范围包括证券、结构金融、反信托诉讼和合规。Hume于1995年加入Kirby McInerney, LLP.自此之后，在他的职业生涯中Hume一直为企业、公共和个人客户提供建议，包括世界上一些大型的机构投资者并帮助他们恢复损失的上百万美元。他的工作为他带来了荣誉和赞许，包括最近被提名为National Law Journal “hot”list 以及2013年度law360 “most feared”list。Hume获许在纽约州和联邦法庭实践法律，包括the United States District Courts for the Southern and Eastern Districts of New York；the United States Court of Appeals for the Second, Fourth, and Fifth Circuits；the Appellate Division of the Supreme Court of the State of New York, First Judicial Department， 以及the United States Supreme Court。他于1988年毕业于奥尔巴尼the State University of New York，持有哲学文学学士学位；Columbia Law School的Columbia Journal of Environmental Law注明编辑，1991年获得法律博士学位。
- Daniel Hume has served on board of directors since October 28, 2025. Mr. Hume currently serves as the Managing Partner of Kirby McInerney, LLP, where his practice foces on securities law regulation, structured finance, antitrt, and civil litigation, and where he has practiced law since 1995. Since June 2015, Mr. Hume has served as a director of TG Therapeutics, Inc., a public biopharmaceutical company and Lirum Therapeutics, a private biopharmaceutical company. Previoly, Mr. Hume was a director of Stemline Therapeutics Inc., a late clinical stage biopharmaceutical company, from 2017 to 2021, and National Holdings Corporation, a financial services company, from 2016 to 2021, until those companies' successful acquisitions. Mr. Hume earned a B.A. in philosophy from the State University of New York at Albany and earned a J.D. from the Columbia University Law School.
- Sagar Lonial
-
Sagar Lonial，于2020年4月被提名为TG Therapeutics, Inc.董事会成员。Sagar Lonial博士在路易斯维尔大学医学院获得医学学位。他在德克萨斯州休斯顿的贝勒医学院完成了实习和住院医师实习，随后在佐治亚州亚特兰大的埃默里大学医学院获得了血液学和肿瘤学研究金。他之前的实验室工作重点是评估纯化的树突状细胞亚群对抗原免疫反应性质的影响，他已经完成了几项评估细胞因子对树突状细胞含量和移植后免疫恢复影响的试验。最近，Lonial博士专注于新型药物的组合作为骨髓瘤的治疗方法。他担任东部合作肿瘤学组骨髓瘤委员会副主席，并担任临床淋巴瘤、骨髓瘤和白血病的骨髓瘤编辑。他曾获得Celgene Young Investigator Award、Indo American Cancer Association终身成就奖、COMY多发性骨髓瘤临床科学卓越奖、癌症护理巨头入选者，目前担任癌症领域的Anne和Bernard Gray家族主席。
Sagar Lonial,was nominated to serve as a member of Tg Therapeutics, Inc. Board of Directors in April 2020. Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology and oncology at Emory University School of Medicine in Atlanta, Georgia. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen, and he has completed several trials evaluating the impact of cytokines on dendritic cell content and post-transplant immune recovery. More recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma. He serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Myeloma editor for Clinical Lymphoma, Myeloma and Leukemia. He has received the Celgene Young Investigator Award, Indo American Cancer Association Lifetime Achievement Award, the COMY Multiple Myeloma Excellence Award for Clinical Science, and the Giants of Cancer Care inductee, and currently holds the Anne and Bernard Gray Family Chair in Cancer. - Sagar Lonial，于2020年4月被提名为TG Therapeutics, Inc.董事会成员。Sagar Lonial博士在路易斯维尔大学医学院获得医学学位。他在德克萨斯州休斯顿的贝勒医学院完成了实习和住院医师实习，随后在佐治亚州亚特兰大的埃默里大学医学院获得了血液学和肿瘤学研究金。他之前的实验室工作重点是评估纯化的树突状细胞亚群对抗原免疫反应性质的影响，他已经完成了几项评估细胞因子对树突状细胞含量和移植后免疫恢复影响的试验。最近，Lonial博士专注于新型药物的组合作为骨髓瘤的治疗方法。他担任东部合作肿瘤学组骨髓瘤委员会副主席，并担任临床淋巴瘤、骨髓瘤和白血病的骨髓瘤编辑。他曾获得Celgene Young Investigator Award、Indo American Cancer Association终身成就奖、COMY多发性骨髓瘤临床科学卓越奖、癌症护理巨头入选者，目前担任癌症领域的Anne和Bernard Gray家族主席。
- Sagar Lonial,was nominated to serve as a member of Tg Therapeutics, Inc. Board of Directors in April 2020. Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology and oncology at Emory University School of Medicine in Atlanta, Georgia. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen, and he has completed several trials evaluating the impact of cytokines on dendritic cell content and post-transplant immune recovery. More recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma. He serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Myeloma editor for Clinical Lymphoma, Myeloma and Leukemia. He has received the Celgene Young Investigator Award, Indo American Cancer Association Lifetime Achievement Award, the COMY Multiple Myeloma Excellence Award for Clinical Science, and the Giants of Cancer Care inductee, and currently holds the Anne and Bernard Gray Family Chair in Cancer.
- Laurence N. Charney
-
Laurence N. Charney，2011年4月被任命为公司董事，在他35年多的职业生涯中，担任合伙人、业务领导和高级顾问。自从Ernst & Young退休以来，他担任董事会、高级管理、早期风险投资者、私营业务和中小盘上市公司的商务策划师和财务顾问，遍及消费品、能源、房地产、高科技和软件、媒体和娱乐，以及非盈利机构等。他最近是在Marvel Entertainment, Inc., Pure BioFuels, Inc., Mrs. Fields Original 首席运营官kies及Iconix Brand Group, Inc.董事会任职。2012年4月他被任命至TG Therapeutics, Inc.的董事会。他是Hofstra University毕业生，获有工商管理会计学士学位，他还完成了Columbia University高级硕士课程。他是美国注册会计师协会和纽约州注册会计师协会的活跃会员。
Laurence N. Charney,has served on Tg Therapeutics, Inc. Board since April 2012. Since 2007, Mr. Charney has served as a business strategist and financial advisor to Boards, CEOs and investors. Previously, from 1970 through June 2007, Mr. Charney was a senior audit partner at Ernst & Young, LLP, a registered public accounting firm, retiring as a practice leader in the Americas Quality and Risk Management Group. Mr. Charney currently serves as a director and audit committee chairman of Kenon Holdings Ltd. In addition, Mr. Charney previously served as a director and audit committee member of Pacific Drillings S.A, Marvel Entertainment, Inc., and other growth-oriented companies. In addition to his extensive experience on the boards of various corporate entities, Mr. Charney is also very active on the boards of several non-profit organizations. Mr. Charney graduated with a B.B.A. degree from Hofstra University and completed the Executive MBA in Business program at Columbia University. - Laurence N. Charney，2011年4月被任命为公司董事，在他35年多的职业生涯中，担任合伙人、业务领导和高级顾问。自从Ernst & Young退休以来，他担任董事会、高级管理、早期风险投资者、私营业务和中小盘上市公司的商务策划师和财务顾问，遍及消费品、能源、房地产、高科技和软件、媒体和娱乐，以及非盈利机构等。他最近是在Marvel Entertainment, Inc., Pure BioFuels, Inc., Mrs. Fields Original 首席运营官kies及Iconix Brand Group, Inc.董事会任职。2012年4月他被任命至TG Therapeutics, Inc.的董事会。他是Hofstra University毕业生，获有工商管理会计学士学位，他还完成了Columbia University高级硕士课程。他是美国注册会计师协会和纽约州注册会计师协会的活跃会员。
- Laurence N. Charney,has served on Tg Therapeutics, Inc. Board since April 2012. Since 2007, Mr. Charney has served as a business strategist and financial advisor to Boards, CEOs and investors. Previously, from 1970 through June 2007, Mr. Charney was a senior audit partner at Ernst & Young, LLP, a registered public accounting firm, retiring as a practice leader in the Americas Quality and Risk Management Group. Mr. Charney currently serves as a director and audit committee chairman of Kenon Holdings Ltd. In addition, Mr. Charney previously served as a director and audit committee member of Pacific Drillings S.A, Marvel Entertainment, Inc., and other growth-oriented companies. In addition to his extensive experience on the boards of various corporate entities, Mr. Charney is also very active on the boards of several non-profit organizations. Mr. Charney graduated with a B.B.A. degree from Hofstra University and completed the Executive MBA in Business program at Columbia University.
- Michael S. Weiss
-
Michael S. Weiss，2011年12月起担任TG的执行主席、临时首席执行官和总裁。他是Opus Point Partners的联合创始人，2008年起担任起管理合伙人和主席。他获有Columbia Law School的法律博士学位，以及The University at Albany的金融学学士学位。他的职业生涯起始于在Cravath, Swaine & Moore担任律师。1999年，他创立Access Oncology，该公司2004年被Keryx Biopharmaceuticals （NASDAQ： KERX）收购。此后，他仍旧担任Keryx的首席执行官，带领公司在顶峰时达到10亿美元市值。在Keryx期间，通过上市和私募发行，他筹集过1.5亿美元的权益资本；执行过1亿美元的战略联盟，与FDA谈判过众多特殊方案评价，管理过多家大型临床试验公司。
Michael S. Weiss has served as Chairman of Mtang Bio, Inc. Board since May 2015 and has also served as Mtang Bio, Inc. Executive Chairman since January 2017. He previoly served as Mtang Bio, Inc. interim President & Chief Executive Officer from March 2015 to April 2017. He is also a board member and the Executive Vice Chairman, Strategic Development of Fortress Biotech, Inc., a position he has held since February 2014, and previoly served as the Chairman of the board of directors of Checkpoint Therapeutics, Inc., prior to its acquisition by Sun Pharmaceuticals in May 2025. Since December 2011, Mr. iss has served in multiple capacities at TG Therapeutics, Inc., and is currently its Chairman, President and Chief Executive Officer. Mr. iss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. He began his professional career as a lawyer with Cravath, Swaine & Moore LLP. From 2002 to 2009, Mr. iss was the Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, Inc. Additionally, Mr. iss co founded and served as Co Portfolio Manager and Managing Partner of Op Point Partners, LLC from 2009 to 2019. - Michael S. Weiss，2011年12月起担任TG的执行主席、临时首席执行官和总裁。他是Opus Point Partners的联合创始人，2008年起担任起管理合伙人和主席。他获有Columbia Law School的法律博士学位，以及The University at Albany的金融学学士学位。他的职业生涯起始于在Cravath, Swaine & Moore担任律师。1999年，他创立Access Oncology，该公司2004年被Keryx Biopharmaceuticals （NASDAQ： KERX）收购。此后，他仍旧担任Keryx的首席执行官，带领公司在顶峰时达到10亿美元市值。在Keryx期间，通过上市和私募发行，他筹集过1.5亿美元的权益资本；执行过1亿美元的战略联盟，与FDA谈判过众多特殊方案评价，管理过多家大型临床试验公司。
- Michael S. Weiss has served as Chairman of Mtang Bio, Inc. Board since May 2015 and has also served as Mtang Bio, Inc. Executive Chairman since January 2017. He previoly served as Mtang Bio, Inc. interim President & Chief Executive Officer from March 2015 to April 2017. He is also a board member and the Executive Vice Chairman, Strategic Development of Fortress Biotech, Inc., a position he has held since February 2014, and previoly served as the Chairman of the board of directors of Checkpoint Therapeutics, Inc., prior to its acquisition by Sun Pharmaceuticals in May 2025. Since December 2011, Mr. iss has served in multiple capacities at TG Therapeutics, Inc., and is currently its Chairman, President and Chief Executive Officer. Mr. iss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. He began his professional career as a lawyer with Cravath, Swaine & Moore LLP. From 2002 to 2009, Mr. iss was the Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, Inc. Additionally, Mr. iss co founded and served as Co Portfolio Manager and Managing Partner of Op Point Partners, LLC from 2009 to 2019.
- Yann Echelard
-
Yann Echelard，2012年11月被提任至董事会。他2012年起担任rEVO Biologics的总裁，在研究和生物制药领域有25余年经验。他获有Universit¨| de Montr¨|al的博士学位，在Montreal McGill University的Ludwig癌症研究所完成博士后项目。作为Roche Institute和Harvard University （发育生物学）的访问科学家，他在刺猬的基因分离和表征方面起关键作用，这是首次被确认的脊椎动物形态因子。1994至2010年，他在Genzyme Transgenics Corporation 和GTC Biotherapeutics担任包括研发部副总裁在内的日益重要的职务。1998年，他带领科学团队，首次执行山羊体细胞核转移（克隆）。专注于企业发展，2006年，他带头与LFB Biotechnologies成立合资公司，专注于血浆蛋白和重组单克隆抗体开发。这种合作关系促使2010年12月LFB收购了GTC Biotherapeutics, Inc.。
Yann Echelard,has served on Tg Therapeutics, Inc. Board since November 2012. Dr. Echelard, current Operating Partner at Flagship Pioneering, has over 30 years of research and biopharmaceutical experience. Dr. Echelard holds a Ph.D. from Université de Montréal and has completed post-doctoral studies at Ludwig Institute of Cancer Research in Montreal (McGill University). As a visiting scientist at the Roche Institute and at Harvard University (Developmental Biology), he had a key role in the isolation and characterization of the Hedgehog genes, the first identified vertebrate morphogens. From 1994 to 2010, he progressed through various positions of increasing responsibility at Genzyme Transgenics Corporation and at GTC Biotherapeutics, including Vice President of Research and Development. In 1998, he led the scientific team that first performed goat somatic cell nuclear transfer (cloning). Focusing on Corporate Development, Dr. Echelard spearheaded the creation of a collaborative Joint Venture with LFB Biotechnologies in 2006, developing recombinant plasma proteins and monoclonal antibodies. This close collaboration led to the acquisition of GTC Biotherapeutics, Inc. by LFB in December 2010. In January of 2013, Dr. Echelard became the President and Chief Executive Officer of rEVO Biologics, Inc., the successor of GTC Biotherapeutics, Inc., a position he held until April 2018. Since joining Flagship Pioneering in 2018, Dr. Echelard has successively served as Founding President of Ring Therapeutics, Cellarity, Laronde, ProFound Therapeutics, Ampersand biomedicine, during their Series A Phase. - Yann Echelard，2012年11月被提任至董事会。他2012年起担任rEVO Biologics的总裁，在研究和生物制药领域有25余年经验。他获有Universit¨| de Montr¨|al的博士学位，在Montreal McGill University的Ludwig癌症研究所完成博士后项目。作为Roche Institute和Harvard University （发育生物学）的访问科学家，他在刺猬的基因分离和表征方面起关键作用，这是首次被确认的脊椎动物形态因子。1994至2010年，他在Genzyme Transgenics Corporation 和GTC Biotherapeutics担任包括研发部副总裁在内的日益重要的职务。1998年，他带领科学团队，首次执行山羊体细胞核转移（克隆）。专注于企业发展，2006年，他带头与LFB Biotechnologies成立合资公司，专注于血浆蛋白和重组单克隆抗体开发。这种合作关系促使2010年12月LFB收购了GTC Biotherapeutics, Inc.。
- Yann Echelard,has served on Tg Therapeutics, Inc. Board since November 2012. Dr. Echelard, current Operating Partner at Flagship Pioneering, has over 30 years of research and biopharmaceutical experience. Dr. Echelard holds a Ph.D. from Université de Montréal and has completed post-doctoral studies at Ludwig Institute of Cancer Research in Montreal (McGill University). As a visiting scientist at the Roche Institute and at Harvard University (Developmental Biology), he had a key role in the isolation and characterization of the Hedgehog genes, the first identified vertebrate morphogens. From 1994 to 2010, he progressed through various positions of increasing responsibility at Genzyme Transgenics Corporation and at GTC Biotherapeutics, including Vice President of Research and Development. In 1998, he led the scientific team that first performed goat somatic cell nuclear transfer (cloning). Focusing on Corporate Development, Dr. Echelard spearheaded the creation of a collaborative Joint Venture with LFB Biotechnologies in 2006, developing recombinant plasma proteins and monoclonal antibodies. This close collaboration led to the acquisition of GTC Biotherapeutics, Inc. by LFB in December 2010. In January of 2013, Dr. Echelard became the President and Chief Executive Officer of rEVO Biologics, Inc., the successor of GTC Biotherapeutics, Inc., a position he held until April 2018. Since joining Flagship Pioneering in 2018, Dr. Echelard has successively served as Founding President of Ring Therapeutics, Cellarity, Laronde, ProFound Therapeutics, Ampersand biomedicine, during their Series A Phase.
- Kenneth Hoberman
-
Kenneth Hoberman于2013年3月被任命为Stemline的首席运营官。在那之前，自2012年2月以来担任本公司的运营副总裁。2004-2012年期间，曾是Keryx Biopharmaceuticals股份有限公司的企业和商业开发副总裁，致力于保证多种渠道资本，包括通过公共和私有发行的超过200000000美元的股本投资。他还曾发起和组织过一个100000000美元战略联盟，以及建立、协商和准备了12个许可和运营合同，帮助该公司的市场资本成长到超过10亿美元。此前，他曾是一家医疗顾问公司- Hawkins BioVentures的总经理。曾从波士顿大学（Boston University）获得他的理学和文学士学位，以及完成了在哥伦比亚大学（Columbia University）的学士后学习。
Kenneth Hoberman,has extensive financial, investor relations, corporate governance, operational and business development experience, including M&A, strategic alliances and partnerships. Mr. Hoberman has served as the Chief Operating Officer of Stemline Therapeutics, Inc. since 2013. While at Stemline, he helped lead the company from an early-stage drug development company to a fully integrated commercial entity including through the company's successful initial public offering. Mr. Hoberman also led the M&A transaction resulting in the acquisition of Stemline by the Menarini Group in June 2020. He was previously Vice President of Corporate and Business Development of Keryx Biopharmaceuticals, Inc., where he led the company's business strategy for Auryxia, including its in-licensing and Japanese partnership. Mr. Hoberman is on the Board of Directors of TG Therapeutics, Inc. (Nasdaq: TGTX).Mr. Hoberman holds a B.S.B.A. in Finance from Boston University and completed post-baccalaureate studies at Columbia University. - Kenneth Hoberman于2013年3月被任命为Stemline的首席运营官。在那之前，自2012年2月以来担任本公司的运营副总裁。2004-2012年期间，曾是Keryx Biopharmaceuticals股份有限公司的企业和商业开发副总裁，致力于保证多种渠道资本，包括通过公共和私有发行的超过200000000美元的股本投资。他还曾发起和组织过一个100000000美元战略联盟，以及建立、协商和准备了12个许可和运营合同，帮助该公司的市场资本成长到超过10亿美元。此前，他曾是一家医疗顾问公司- Hawkins BioVentures的总经理。曾从波士顿大学（Boston University）获得他的理学和文学士学位，以及完成了在哥伦比亚大学（Columbia University）的学士后学习。
- Kenneth Hoberman,has extensive financial, investor relations, corporate governance, operational and business development experience, including M&A, strategic alliances and partnerships. Mr. Hoberman has served as the Chief Operating Officer of Stemline Therapeutics, Inc. since 2013. While at Stemline, he helped lead the company from an early-stage drug development company to a fully integrated commercial entity including through the company's successful initial public offering. Mr. Hoberman also led the M&A transaction resulting in the acquisition of Stemline by the Menarini Group in June 2020. He was previously Vice President of Corporate and Business Development of Keryx Biopharmaceuticals, Inc., where he led the company's business strategy for Auryxia, including its in-licensing and Japanese partnership. Mr. Hoberman is on the Board of Directors of TG Therapeutics, Inc. (Nasdaq: TGTX).Mr. Hoberman holds a B.S.B.A. in Finance from Boston University and completed post-baccalaureate studies at Columbia University.
高管简历
中英对照 | 中文 | 英文- Michael S. Weiss
Michael S. Weiss，2011年12月起担任TG的执行主席、临时首席执行官和总裁。他是Opus Point Partners的联合创始人，2008年起担任起管理合伙人和主席。他获有Columbia Law School的法律博士学位，以及The University at Albany的金融学学士学位。他的职业生涯起始于在Cravath, Swaine & Moore担任律师。1999年，他创立Access Oncology，该公司2004年被Keryx Biopharmaceuticals （NASDAQ： KERX）收购。此后，他仍旧担任Keryx的首席执行官，带领公司在顶峰时达到10亿美元市值。在Keryx期间，通过上市和私募发行，他筹集过1.5亿美元的权益资本；执行过1亿美元的战略联盟，与FDA谈判过众多特殊方案评价，管理过多家大型临床试验公司。
Michael S. Weiss has served as Chairman of Mtang Bio, Inc. Board since May 2015 and has also served as Mtang Bio, Inc. Executive Chairman since January 2017. He previoly served as Mtang Bio, Inc. interim President & Chief Executive Officer from March 2015 to April 2017. He is also a board member and the Executive Vice Chairman, Strategic Development of Fortress Biotech, Inc., a position he has held since February 2014, and previoly served as the Chairman of the board of directors of Checkpoint Therapeutics, Inc., prior to its acquisition by Sun Pharmaceuticals in May 2025. Since December 2011, Mr. iss has served in multiple capacities at TG Therapeutics, Inc., and is currently its Chairman, President and Chief Executive Officer. Mr. iss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. He began his professional career as a lawyer with Cravath, Swaine & Moore LLP. From 2002 to 2009, Mr. iss was the Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, Inc. Additionally, Mr. iss co founded and served as Co Portfolio Manager and Managing Partner of Op Point Partners, LLC from 2009 to 2019.- Michael S. Weiss，2011年12月起担任TG的执行主席、临时首席执行官和总裁。他是Opus Point Partners的联合创始人，2008年起担任起管理合伙人和主席。他获有Columbia Law School的法律博士学位，以及The University at Albany的金融学学士学位。他的职业生涯起始于在Cravath, Swaine & Moore担任律师。1999年，他创立Access Oncology，该公司2004年被Keryx Biopharmaceuticals （NASDAQ： KERX）收购。此后，他仍旧担任Keryx的首席执行官，带领公司在顶峰时达到10亿美元市值。在Keryx期间，通过上市和私募发行，他筹集过1.5亿美元的权益资本；执行过1亿美元的战略联盟，与FDA谈判过众多特殊方案评价，管理过多家大型临床试验公司。
- Michael S. Weiss has served as Chairman of Mtang Bio, Inc. Board since May 2015 and has also served as Mtang Bio, Inc. Executive Chairman since January 2017. He previoly served as Mtang Bio, Inc. interim President & Chief Executive Officer from March 2015 to April 2017. He is also a board member and the Executive Vice Chairman, Strategic Development of Fortress Biotech, Inc., a position he has held since February 2014, and previoly served as the Chairman of the board of directors of Checkpoint Therapeutics, Inc., prior to its acquisition by Sun Pharmaceuticals in May 2025. Since December 2011, Mr. iss has served in multiple capacities at TG Therapeutics, Inc., and is currently its Chairman, President and Chief Executive Officer. Mr. iss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. He began his professional career as a lawyer with Cravath, Swaine & Moore LLP. From 2002 to 2009, Mr. iss was the Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, Inc. Additionally, Mr. iss co founded and served as Co Portfolio Manager and Managing Partner of Op Point Partners, LLC from 2009 to 2019.
- Sean A. Power
Sean A. Power，2011年12月起担任公司首席财务官，现任Opus Point Partners的首席财务官。加入公司前，2006至2011年，他在Keryx Biopharmaceuticals, Inc. KERX工作， 担任财务总监。任职期间，他参与所有资本募集和交易审批。他也负责Keryx的SEC的规章合规工作。加入Keryx前，他在独立会计师事务所KPMG, LLP工作，担任高级合伙人。他获得Siena College会计学学士学位，也是美国注册会计师协会成员（American Institute of Certified Public Accountants）。
Sean A. Power,has served as Tg Therapeutics, Inc. Chief Financial Officer since December 2011. Mr. Power joined the Company from Keryx Biopharmaceuticals, Inc., where he served as Corporate Controller from 2006 to 2011. During his tenure there, Mr. Power was involved in all capital raising and licensing transactions. He was also responsible for leading Keryx's compliance with SEC rules and regulations. Prior to joining Keryx, he was with KPMG LLP, independent certified public accountants. Additionally, Mr. Power served as Chief Financial Officer of Opus Point Partners, LLC from 2011 to 2019. Mr. Power received a B.B.A in accounting from Siena College and is a member of the American Institute of Certified Public Accountants.- Sean A. Power，2011年12月起担任公司首席财务官，现任Opus Point Partners的首席财务官。加入公司前，2006至2011年，他在Keryx Biopharmaceuticals, Inc. KERX工作， 担任财务总监。任职期间，他参与所有资本募集和交易审批。他也负责Keryx的SEC的规章合规工作。加入Keryx前，他在独立会计师事务所KPMG, LLP工作，担任高级合伙人。他获得Siena College会计学学士学位，也是美国注册会计师协会成员（American Institute of Certified Public Accountants）。
- Sean A. Power,has served as Tg Therapeutics, Inc. Chief Financial Officer since December 2011. Mr. Power joined the Company from Keryx Biopharmaceuticals, Inc., where he served as Corporate Controller from 2006 to 2011. During his tenure there, Mr. Power was involved in all capital raising and licensing transactions. He was also responsible for leading Keryx's compliance with SEC rules and regulations. Prior to joining Keryx, he was with KPMG LLP, independent certified public accountants. Additionally, Mr. Power served as Chief Financial Officer of Opus Point Partners, LLC from 2011 to 2019. Mr. Power received a B.B.A in accounting from Siena College and is a member of the American Institute of Certified Public Accountants.